FDA 483 - CSL Plasma Inc. - August 11, 2021

An FDA inspection of CSL Plasma Inc's plasmapheresis center in Cincinnati, OH, identified one observation. The firm failed to ensure the suitability of blood donations due to an inaccurate and incomplete medication list used for donor screening. This indicates a potential risk in donor eligibility determination.